279 related articles for article (PubMed ID: 35240933)
1. Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches.
Absalon J; Simon R; Radley D; Giardina PC; Koury K; Jansen KU; Anderson AS
Hum Vaccin Immunother; 2022 Dec; 18(1):2037350. PubMed ID: 35240933
[TBL] [Abstract][Full Text] [Related]
2. The Italian arm of the PREPARE study: an international project to evaluate and license a maternal vaccine against group B streptococcus.
Berardi A; Cassetti T; Creti R; Vocale C; Ambretti S; Sarti M; Facchinetti F; Cose S; ; Heath P; Le Doare K
Ital J Pediatr; 2020 Oct; 46(1):160. PubMed ID: 33115542
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States.
Kim SY; Nguyen C; Russell LB; Tomczyk S; Abdul-Hakeem F; Schrag SJ; Verani JR; Sinha A
Vaccine; 2017 Oct; 35(45):6238-6247. PubMed ID: 28951085
[TBL] [Abstract][Full Text] [Related]
4. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.
Madhi SA; Dangor Z; Heath PT; Schrag S; Izu A; Sobanjo-Ter Meulen A; Dull PM
Vaccine; 2013 Aug; 31 Suppl 4():D52-7. PubMed ID: 23973347
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa.
Kim SY; Russell LB; Park J; Verani JR; Madhi SA; Cutland CL; Schrag SJ; Sinha A
Vaccine; 2014 Apr; 32(17):1954-63. PubMed ID: 24530145
[TBL] [Abstract][Full Text] [Related]
6. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.
Kobayashi M; Schrag SJ; Alderson MR; Madhi SA; Baker CJ; Sobanjo-Ter Meulen A; Kaslow DC; Smith PG; Moorthy VS; Vekemans J
Vaccine; 2019 Nov; 37(50):7307-7314. PubMed ID: 28017431
[TBL] [Abstract][Full Text] [Related]
7. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine.
Schrag SJ; Verani JR
Vaccine; 2013 Aug; 31 Suppl 4():D20-6. PubMed ID: 23219695
[TBL] [Abstract][Full Text] [Related]
8. Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study.
Carreras-Abad C; Cochet M; Hall T; Ramkhelawon L; Khalil A; Peregrine E; Vinayakarao L; Sivarajan S; Hamid R; Planche T; Sheridan E; Winchester S; Plumb J; Djennad A; Andrews N; Le Doare K; Heath P
Health Technol Assess; 2019 Dec; 23(67):1-40. PubMed ID: 31855555
[TBL] [Abstract][Full Text] [Related]
9. Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective?
Oster G; Edelsberg J; Hennegan K; Lewin C; Narasimhan V; Slobod K; Edwards MS; Baker CJ
Vaccine; 2014 Aug; 32(37):4778-85. PubMed ID: 24992717
[TBL] [Abstract][Full Text] [Related]
10. Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.
Verani JR; McGee L; Schrag SJ;
MMWR Recomm Rep; 2010 Nov; 59(RR-10):1-36. PubMed ID: 21088663
[TBL] [Abstract][Full Text] [Related]
11. [Do we need a different approach to GBS screening?].
Szymusik I; Kosińska-Kaczyińska K; Pietrzak B; Wielgoś M
Ginekol Pol; 2014 Jun; 85(6):456-60. PubMed ID: 25029812
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the clinical development of group B streptococcus serotype-specific capsular polysaccharide-based vaccines.
Dzanibe S; Madhi SA
Expert Rev Vaccines; 2018 Jul; 17(7):635-651. PubMed ID: 29961350
[TBL] [Abstract][Full Text] [Related]
13. 20 million pregnant women with group B streptococcus carriage: consequences, challenges, and opportunities for prevention.
Paul P; Gonçalves BP; Le Doare K; Lawn JE
Curr Opin Pediatr; 2023 Apr; 35(2):223-230. PubMed ID: 36749143
[TBL] [Abstract][Full Text] [Related]
14. Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions.
Seale AC; Baker CJ; Berkley JA; Madhi SA; Ordi J; Saha SK; Schrag SJ; Sobanjo-Ter Meulen A; Vekemans J
Vaccine; 2019 Aug; 37(35):4877-4885. PubMed ID: 31303524
[TBL] [Abstract][Full Text] [Related]
15. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC.
Schrag S; Gorwitz R; Fultz-Butts K; Schuchat A
MMWR Recomm Rep; 2002 Aug; 51(RR-11):1-22. PubMed ID: 12211284
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of maternal immunization against neonatal invasive Group B Streptococcus in the Netherlands.
Hahn BA; de Gier B; van Kassel MN; Bijlsma MW; van Leeuwen E; Wouters MGAJ; van der Ende A; van de Beek D; Wallinga J; Hahné SJM; Jan van Hoek A
Vaccine; 2021 May; 39(21):2876-2885. PubMed ID: 33895018
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study.
Giorgakoudi K; O'Sullivan C; Heath PT; Ladhani S; Lamagni T; Ramsay M; Al-Janabi H; Trotter C
Vaccine; 2018 Nov; 36(46):7033-7042. PubMed ID: 30293765
[TBL] [Abstract][Full Text] [Related]
18. Early-onset group B streptococcal disease in the era of maternal screening.
Puopolo KM; Madoff LC; Eichenwald EC
Pediatrics; 2005 May; 115(5):1240-6. PubMed ID: 15867030
[TBL] [Abstract][Full Text] [Related]
19. Preventing the broad spectrum of perinatal morbidity and mortality through group B streptococcal vaccination.
Edwards MS; Gonik B
Vaccine; 2013 Aug; 31 Suppl 4():D66-71. PubMed ID: 23200934
[TBL] [Abstract][Full Text] [Related]
20. Group B Streptococcus Colonization in Late Pregnancy and Invasive Infection in Neonates in China: A Population-Based 3-Year Study.
Zhu Y; Huang J; Lin XZ; Chen C
Neonatology; 2019; 115(4):301-309. PubMed ID: 30808831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
